NPM1 silencing reduces tumour growth and MAPK signalling in prostate cancer cells.
The chaperone nucleophosmin (NPM1) is over-expressed in the epithelial compartment of prostate tumours compared to adjacent healthy epithelium and may represent one of the key actors that support the neoplastic phenotype of prostate adenocarcinoma cells. Yet, the mechanisms that underlie NPM1 mediat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4010470?pdf=render |
| _version_ | 1811320837718933504 |
|---|---|
| author | Gaëlle Loubeau Rafik Boudra Sabrina Maquaire Corinne Lours-Calet Claude Beaudoin Pierre Verrelle Laurent Morel |
| author_facet | Gaëlle Loubeau Rafik Boudra Sabrina Maquaire Corinne Lours-Calet Claude Beaudoin Pierre Verrelle Laurent Morel |
| author_sort | Gaëlle Loubeau |
| collection | DOAJ |
| description | The chaperone nucleophosmin (NPM1) is over-expressed in the epithelial compartment of prostate tumours compared to adjacent healthy epithelium and may represent one of the key actors that support the neoplastic phenotype of prostate adenocarcinoma cells. Yet, the mechanisms that underlie NPM1 mediated phenotype remain elusive in the prostate. To better understand NPM1 functions in prostate cancer cells, we sought to characterize its impact on prostate cancer cells behaviour and decipher the mechanisms by which it may act. Here we show that NPM1 favors prostate tumour cell migration, invasion and colony forming. Furthermore, knockdown of NPM1 leads to a decrease in the growth of LNCaP-derived tumours grafted in Nude mice in vivo. Such oncogenic-like properties are found in conjunction with a positive regulation of NPM1 on the ERK1/2 (Extracellular signal-Regulated Kinases 1/2) kinase phosphorylation in response to EGF (Epidermal Growth Factor) stimulus, which is critical for prostate cancer progression following the setting of an autonomous production of the growth factor. NPM1 could then be a target to switch off specifically ERK1/2 pathway activation in order to decrease or inhibit cancer cell growth and migration. |
| first_indexed | 2024-04-13T13:06:14Z |
| format | Article |
| id | doaj.art-ab51b914999548fabe4b61876b442441 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T13:06:14Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-ab51b914999548fabe4b61876b4424412022-12-22T02:45:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0195e9629310.1371/journal.pone.0096293NPM1 silencing reduces tumour growth and MAPK signalling in prostate cancer cells.Gaëlle LoubeauRafik BoudraSabrina MaquaireCorinne Lours-CaletClaude BeaudoinPierre VerrelleLaurent MorelThe chaperone nucleophosmin (NPM1) is over-expressed in the epithelial compartment of prostate tumours compared to adjacent healthy epithelium and may represent one of the key actors that support the neoplastic phenotype of prostate adenocarcinoma cells. Yet, the mechanisms that underlie NPM1 mediated phenotype remain elusive in the prostate. To better understand NPM1 functions in prostate cancer cells, we sought to characterize its impact on prostate cancer cells behaviour and decipher the mechanisms by which it may act. Here we show that NPM1 favors prostate tumour cell migration, invasion and colony forming. Furthermore, knockdown of NPM1 leads to a decrease in the growth of LNCaP-derived tumours grafted in Nude mice in vivo. Such oncogenic-like properties are found in conjunction with a positive regulation of NPM1 on the ERK1/2 (Extracellular signal-Regulated Kinases 1/2) kinase phosphorylation in response to EGF (Epidermal Growth Factor) stimulus, which is critical for prostate cancer progression following the setting of an autonomous production of the growth factor. NPM1 could then be a target to switch off specifically ERK1/2 pathway activation in order to decrease or inhibit cancer cell growth and migration.http://europepmc.org/articles/PMC4010470?pdf=render |
| spellingShingle | Gaëlle Loubeau Rafik Boudra Sabrina Maquaire Corinne Lours-Calet Claude Beaudoin Pierre Verrelle Laurent Morel NPM1 silencing reduces tumour growth and MAPK signalling in prostate cancer cells. PLoS ONE |
| title | NPM1 silencing reduces tumour growth and MAPK signalling in prostate cancer cells. |
| title_full | NPM1 silencing reduces tumour growth and MAPK signalling in prostate cancer cells. |
| title_fullStr | NPM1 silencing reduces tumour growth and MAPK signalling in prostate cancer cells. |
| title_full_unstemmed | NPM1 silencing reduces tumour growth and MAPK signalling in prostate cancer cells. |
| title_short | NPM1 silencing reduces tumour growth and MAPK signalling in prostate cancer cells. |
| title_sort | npm1 silencing reduces tumour growth and mapk signalling in prostate cancer cells |
| url | http://europepmc.org/articles/PMC4010470?pdf=render |
| work_keys_str_mv | AT gaelleloubeau npm1silencingreducestumourgrowthandmapksignallinginprostatecancercells AT rafikboudra npm1silencingreducestumourgrowthandmapksignallinginprostatecancercells AT sabrinamaquaire npm1silencingreducestumourgrowthandmapksignallinginprostatecancercells AT corinnelourscalet npm1silencingreducestumourgrowthandmapksignallinginprostatecancercells AT claudebeaudoin npm1silencingreducestumourgrowthandmapksignallinginprostatecancercells AT pierreverrelle npm1silencingreducestumourgrowthandmapksignallinginprostatecancercells AT laurentmorel npm1silencingreducestumourgrowthandmapksignallinginprostatecancercells |